ABSI stock sentiment todayAbsci Corp
Sentiment verdict
Gossip first, financials second — HOT at 78% confidence.
Last updated · cached analysis, refreshes periodically
ABSI
Absci CorpA high-beta AI-drug discovery play benefiting from the generative AI narrative and high-profile pharma partnerships.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ABSI. Not financial advice.
Price · last 12 months
Gossip
The market is currently viewing Absci as the 'Nvidia of Biotech.' Narrative momentum is driven by their 'zero-shot' generative AI model for antibody design and the strategic collaboration with AstraZeneca. Retail interest is high due to the intersection of LLMs and drug development.
- ·Generative AI hype cycle
- ·AstraZeneca partnership validation
- ·Expansion into internal drug pipeline
- ·Speculation on further Big Pharma licensing deals
Financial
Typical early-stage biotech profile with high cash burn but a significantly bolstered balance sheet following recent equity offerings. Revenue is currently nominal and derived from milestones, not product sales.
- ·Cash runway into late 2026
- ·Negligible debt-to-equity ratio
- ·Triple-digit R&D expense growth
- ·Market cap volatility due to lack of P/E valuation
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $149K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High binary risk associated with clinical trial outcomes
- ·Dependency on partner milestones for short-term liquidity
- ·Execution risk in translating AI designs to wet-lab success
Peer temperature
How direct competitors stack up against ABSI right now.
- NEUTRALSDGRSchrodinger, Inc.
COLDER — More established software revenue base but slower growth narrative compared to Absci's generative AI focus.
See full analysis → - HOTRXDXPrometheus Biosciences (Acquired/Comp: RXRX)
HOTTER — Recursion (RXRX) has deeper NVIDIA integration and a larger scale of automated wet-lab data generation.
See full analysis → - COLDADPTAdaptive Biotechnologies
COLDER — Struggling with restructuring and lacks the 'generative' momentum currently lifting Absci's valuation.
See full analysis →
- ABSI+3.3%
- SDGR-12.6%
- RXDX—
- ADPT-7.8%
Analyst price target
Consensus average of 12 analysts · median 15.00
Source: StockAnalysis.com · updated 2026-10-29
AI-generated analysis for informational purposes only. Not financial advice.